( HANOVER Germany--(BUSINESS WIRE)--Jun ...)Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001,Health

HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for cancer patients. The results of a successfully completed clinical study will be presented to an international audience at the Annual Conference of the American Society for Clinical Oncology (ASCO) in Chicago, USA. ASCO is the most important professional organization of cancer specialists world-wide.

The active substance VPM4001, an immunotherapeutic for cancer treatment, has reached an important stage of development: A clinical phase I/II study with 30 patients successfully completed in 2006 showed that 73 % of patients suffering from advanced, hormone-resistant prostate carcinoma responded positively to the VPM4001 therapy. The primary study parameter, the PSA doubling time, was increased from 63 days to 114 days on average. This promising result has a high statistical significance (p=0.0035). VPM4001 also showed an excellent tolerability profile. The study was carried out at the Institute for Experimental Oncology (Prof. Dr. med. B. Gansbacher) and at the Clinic for Urology (Prof. Dr. med. R. Hartung) of Munich Technical University.

The new vaccine will support the immune system to fight cancer. Based on the promising results, a panel of international experts from the USA, Germany and the Netherlands has recommended the continuation of clinical development of the vaccine as fast as possible. Prostate cancer is the most frequent type of tumor affecting male patients aged 50+ and also the third most frequent cause of death resulting from cancer disease. Each year approx. 420,000 people in Europe and in the USA are affected by prostate cancer. The life-time risk of becoming affected by prostate cancer is 1:6.

VPM4001 is an ideal example for the development of innovative vaccines initiated by VPM. This has lead to the development project being int
'"/>

Page: 1 2
Related medicine technology :

1. Choosing Lab Quality Management Software
2. Optimizing Quality Control Data Management
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib